| amlodipine versus placebo | |||
| IDNT (amlodipine vs PBO), 2001 | Amlodipine 10 mg daily versus placebo | hypertensive patients with nephropathy due to type 2 diabetes | double-blind Follow-up duration: 2.6 years Worldwide |
| fosinopril versus control | |||
| Fogari, 2002 | amlodipine plus fosinopril (5/10 to 15/30 mg/day versus amlodipine (5 to 15 mg/day) | hypertensive patients with type 2 diabetes and microalbuminuria | NA Follow-up duration: NA |
| irbesartan versus amlodipine | |||
| IDNT (irbesartan vs amlodipine), 2001 | Irbesartan 300 mg daily versus amlodipine 10 mg daily | hypertensive patients with nephropathy due to type 2 diabetes | double blind Follow-up duration: 2.6 years Worldwide |
| irbesartan versus placebo | |||
| IDNT (irbesartan vs pbo), 2001 | Irbesartan 300 mg daily versus placebo | hypertensive patients with nephropathy due to type 2 diabetes | double blind Follow-up duration: 2.6 years Worldwide |
| IPDM (150mg), 2001 | irbesartan 150 mg daily versus placebo | hypertensive patients with type 2 diabetes and microalbuminuria | double-blind Follow-up duration: 2 years Worldwide |
| losartan versus placebo | |||
| RENAAL, 2001 | losartan 50 to 100 mg once daily versus placebo | patients with type 2 diabetes and nephropathy | double-blind Follow-up duration: 3.4 y America, Europe, Asia |
| olmesartan versus placebo | |||
| ORIENT, NCT00141453 | olmesartan versus placebo | patients with diabetic Nephropathy and overt proteinuria secondary to type 2 diabetes mellitus | double-blind Japan, Hong Kong |
| ramipril versus placebo | |||
| DIABHYCAR, 2004 | ramipril 1.25 mg/day versus placebo | patients with type 2 diabetes who have microalbuminuria or proteinuria | double-blind Follow-up duration: median 4 years Europe, North Africa |
| telmisartan versus enalapril | |||
| DETAIL, 2004 | telmisartan 80 mg daily versus enalapril 20 mg daily | subjects with type 2 diabetes and early nephropathy | double-blind Follow-up duration: 5 year |
| temisartan versus enalapril | |||
| DETAIL, 2004 | telmisartan 80 mg daily versus enalapril 20 mg daily | subjects with type 2 diabetes and early nephropathy | double-blind Follow-up duration: 5 years northern Europe |
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
